Related content

Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response

By Horváth Zsolt  

Pathology & Oncology Research, Vol. 17, Iss. 3, 2011-09 ,pp. : 541-550

Springer Publishing Company

Access to resources Recommend Favorite

Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers

By Yan Max  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 395-405

Springer Publishing Company

Access to resources Recommend Favorite

Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers

By Takahashi Yuri   Miyoshi Yasuo   Morimoto Koji   Taguchi Tetsuya   Tamaki Yasuhiro   Noguchi Shinzaburo  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 8, 2007-08 ,pp. : 501-509

Springer Publishing Company

Access to resources Recommend Favorite

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer

By Petit Thierry  

Breast Cancer Research and Treatment, Vol. 124, Iss. 2, 2010-11 ,pp. : 387-391

Springer Publishing Company

Access to resources Recommend Favorite

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

By Tham Yee-Lu   Gomez L.   Mohsin Syed   Gutierrez M.   Weiss Heidi   Hilsenbeck Susan   Elledge Richard   Chamness Gary   Osborne C.   Allred D.   Chang Jenny  

Breast Cancer Research and Treatment, Vol. 94, Iss. 3, 2005-12 ,pp. : 279-284

Springer Publishing Company

Access to resources Recommend Favorite